Alector, Inc. key statistics and ratios
In fiscal 2025, Alector, Inc. had return on equity of -181.6%, an operating margin of -741.3%, debt equal to 33.8% of equity and a current ratio of 3.83. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | −874.9% | −207.0% | −539.2% | −925.1% | −18.0% | −103.2% | −156.3% | −144.2% | −741.3% | −912.4% |
| Net margin | −869.6% | −188.8% | −496.7% | −901.6% | −17.5% | −99.8% | −134.3% | −118.4% | −679.2% | −850.1% |
| Free-cash-flow margin | −497.2% | 453.7% | −540.0% | −814.1% | 142.6% | −18.3% | −192.1% | −229.9% | −874.7% | <−999% |
| Return on equity | — | — | — | −82.3% | −12.8% | −51.8% | −74.8% | −91.2% | −181.6% | — |
| Return on assets | — | −16.9% | −28.9% | −41.8% | −5.6% | −16.6% | −18.5% | −21.8% | −37.5% | −47.5% |
| Asset turnover | — | 0.09 | 0.06 | 0.05 | 0.32 | 0.17 | 0.14 | 0.18 | 0.06 | 0.06 |
| Current ratio | — | 6.11 | 5.77 | 6.19 | 5.37 | 7.74 | 3.18 | 3.40 | 3.83 | 5.26 |
| Debt to equity | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 7.9% | 33.8% | — |
| R&D as % of revenue | 800.8% | 263.9% | 473.8% | 743.5% | 91.5% | 157.5% | 197.9% | 184.9% | 584.8% | 715.1% |
| Capital spending as % of revenue | 21.4% | 6.8% | 71.9% | 23.9% | 1.6% | 3.1% | 2.5% | 1.2% | 0.2% | 1.2% |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | −315.7% | −13.4% | <−999% | −433.6% | <−999% | −634.4% | <−999% | −734.7% |
| Net margin | −275.2% | −3.8% | <−999% | −387.7% | <−999% | −597.5% | <−999% | −692.5% |
| Free-cash-flow margin | −332.1% | −101.8% | <−999% | −623.0% | −997.6% | −668.4% | <−999% | <−999% |
| Current ratio | 3.29 | 3.40 | 3.34 | 3.78 | 3.76 | 3.83 | 5.25 | 5.26 |
| Debt to equity | — | 7.4% | 10.0% | 13.4% | 16.7% | 31.6% | 94.1% | — |
| R&D as % of revenue | 312.9% | 85.7% | 909.2% | 350.7% | 900.3% | 520.5% | >999% | 586.1% |
Financial health
- Short-term assets cover short-term liabilities $180m of assets due within a year against $34m of liabilities due within a year.
- Short-term assets cover long-term liabilities $180m short-term assets against $179m of longer-dated liabilities.
- More cash than debt $60m of cash against $10m of debt.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt −$158m of operating cash flow against $10m of debt.
- Operating profit covers interest at least five times over No material interest expense reported.
Moat
Weak moat
How hard Alector's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -27.0% of total assets over 8 years.
- Durability 10 / 20
Operating margin has been a median -318.0%; its worst year was -1000.5%.
- Cash conversion 1 / 20
Free cash flow was positive in 1 of 8 years, at a median -363.0% of revenue.
- Discipline 0 / 20
The diluted share count rose 36.9% over five years; stock-based pay has been a median 59.1% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (14 before it).
Compare with peers
- Lineage Cell Therapeutics, Inc. statistics
- Keros Therapeutics, Inc. statistics
- Surrozen, Inc. statistics
- Mindwalk Holdings Corp. statistics
- Proqr Therapeutics N.V. statistics
Head to head: ALEC vs LCTXALEC vs KROSALEC vs SRZN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies